David A. Jones, PhD
- Colon Cancer
- DNA Methylation
- Genes, APC
- Cancer Therapeutic Development
- Departments: Biomedical Informatics - Adjunct Assistant Professor
- Cancer Center Programs: Nuclear Control of Cell Growth & Differentiation
Academic Office Information
Huntsman Cancer Institute
2000 Circle of Hope, Room: 3280
Salt Lake City, UT 84112
David A. Jones, PhD, is Professor of Oncological Sciences, a Huntsman Cancer Institute investigator, and member of the Nuclear Control of Cell Growth and Differentiation program. Dr. Jones holds a degree in Pharmacology and is an established investigator with research interests focused on understanding the processes of intestinal cell fating and in defining the earliest cellular perturbations that follow loss of APC in the initiation of colorectal cancer. Dr. Jones’ work also evaluates novel target pathways for drug discovery and clinical trials in colon cancer. Dr. Jones’ work has moved from lab bench investigations to prevention and therapeutic clinical trials in collaboration with other Cancer Center investigators. Dr. Jones has extensive experience in the cancer drug discovery industry and is uniquely suited to serve as an effective advocate for both basic and translational efforts within the Cancer Center. Dr. Jones has led multidisciplinary cancer drug target discovery program teams at Pharmacia and Upjohn and continues to consult on cancer drug discovery for various biotechnology and pharmaceutical companies. He co-founded Zicthus Therapeutics to support evaluation and development of potential lead compounds.
|Postdoctoral Fellowship||University of Utah, Human Molecular Biology & Genetics
|Doctoral Training||University of Colorado Health Sciences Center
|Undergraduate||University of Michigan
Cellular & Molecular Biology
- Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude GJ, Miles RR, Cox JE, Frazer JK, Deininger M, Balan K, Sigman M, Muschen M, Perova T, Johnson R, Montpellier B, Guidos CJ, Jones DA, Trede NS (2012). Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood, 119(24), 5621-31.
- Maddox J, Shakya A, South S, Shelton D, Andersen JN, Chidester S, Kang J, Gligorich KM, Jones DA, Spangrude GJ, Welm BE, Tantin D (2012). Transcription factor Oct1 is a somatic and cancer stem cell determinant. PLoS Genet, 8(11), e1003048.
- Rai K, Sarkar S, Broadbent TJ, Voas M, Grossmann KF, Nadauld LD, Dehghanizadeh S, Hagos FT, Li Y, Toth RK, Chidester S, Bahr TM, Johnson WE, Sklow B, Burt R, Cairns BR, Jones DA (2010). DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC. Cell, 142(6), 930-42.
- Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, Broadbent T, Sarkar S, Burt RW, Jones DA (2009). A two-step model for colon adenoma initiation and progression caused by APC loss. Cell, 137(4), 623-34.
- Link PA, Baer MR, James SR, Jones DA, Karpf AR (2008). p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res, 68(22), 9358-66.
- Eisinger AL, Nadauld LD, Shelton DN, Prescott SM, Stafforini DM, Jones DA (2007). Retinoic acid inhibits beta-catenin through suppression of Cox-2: a role for truncated adenomatous polyposis coli. J Biol Chem, 282(40), 29394-400.
- Hammoud SS, Cairns BR, Jones DA (2013). Epigenetic regulation of colon cancer and intestinal stem cells. [Review]. Curr Opin Cell Biol, 25(2), 177-83.
- Andersen A, Jones DA (2013). APC and DNA demethylation in cell fate specification and intestinal cancer. [Review]. Adv Exp Med Biol, 754, 167-77.
- Phelps RA, Broadbent TJ, Stafforini DM, Jones DA (2009). New perspectives on APC control of cell fate and proliferation in colorectal cancer. [Review]. Cell Cycle, 8(16), 2549-56.